Intellia Therapeutics (NTLA) Other financing activities (2015 - 2016)
Intellia Therapeutics (NTLA) reported Other financing activities of $1.7 million for Q3 2016, up 669.3% on a QoQ basis from $215000.0 in Q2 2016.
Intellia Therapeutics (NTLA) has 2 years of Other financing activities data on file, last reported at $1.7 million in Q3 2016.
- Quarterly Other financing activities changed N/A year-over-year to $1.7 million in Q3 2016, while the trailing twelve-month figure through Dec 2016 was $2.8 million (changed N/A YoY) and the FY2018 annual result came in at $424000.0, changed N/A from the prior year.
- Other financing activities climbed to $1.7 million in Q3 2016 per NTLA's latest filing, from $215000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $1.7 million in Q3 2016 and bottomed at $207000.0 in Q4 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 1.65 Mn |
| Sep 30, 2016 | 1.65 Mn |
| Jun 30, 2016 | 215,000.00 |
| Jun 30, 2016 | 215,000.00 |
| Mar 31, 2016 | 895,000.00 |
| Mar 31, 2016 | 895,000.00 |
| Dec 31, 2015 | 207,000.00 |
| Dec 31, 2015 | 207,000.00 |